| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Precise, personalized therapy
Identify drug-gene interactions to maximize medicine
Pharmacogenomics (PGx) is a rapidly evolving field with the potential to affect every patient, everywhere. Studies suggest most individuals possess at least one actionable genetic variant that predisposes drug response. Establishing patients' genetic profiles allows physicians to select patient-specific medications that optimize therapeutic efficacy while avoiding adverse drug reactions.
Therapeutic areas impacted by PGx
Paving the way for PGx implementation
The Molecular Technologies Laboratory at Mayo Clinic develops and validates PGx testing in partnership with the Center for Individualized Medicine and the Schulze Center for Novel Therapeutics. Evaluations include actionable genes with a high level of clinical evidence. Categorization of medication recommendations by drug class and reference source ensures easy interpretations for all audiences.
Increase your PGx IQ
Understanding the myriad implications that PGx testing has on patient treatment outcomes is integral to harnessing the full power of this emerging field. To educate providers about current and future PGx applications, Mayo Clinic offers a one-of-a-kind, online certificate course that guides attendees through foundational pharmacogenomics concepts and advanced decision-making. Engaging lectures, expert panels, case-based presentations, and patient role-play activities educate attendees on pharmacogenomics fundamentals, test interpretation, and tips on implementing pharmacogenomics into your practice.
The right drug for the right patient at the right dose
A comprehensive resource for ordering, interpreting, and understanding PGx testing. Indications for pharmacogenomic testing may include:
Comprehensive PGx panels
PSYQP | Psychotropic Pharmacogenomics Gene Panel, Varies
PGXQP | Focused Pharmacogenomics Panel, Varies
Medication Targeted Panels
Guides therapy when analyzing multiple drug interactions that fall into the same drug class or patients with polypharmacy.
Single Gene Orders
Guides therapy when evaluating single medications or genes not included in the comprehensive panels.
Test in Focus
Ann Moyer, M.D., Ph.D., explains Mayo Clinic Labs’ new focused pharmacogenomics panel, a real-time, PCR-based testing approach that assesses 10 genes known for their drug-gene associations, to provide guidance on medication selection for patients across a variety of specialities.
The Latest
In this month's "Hot Topic," Paul Jannetto, Ph.D., identifies how to determine new vs. residual use of marijuana in a patient, and teaches how to calculate the carboxy-tetrahydrocannabinol (carboxy-THC) to creatinine ratio along with a decision ratio by demonstrating its clinical utility via case study.
PACE/State of CA/State of FL - In this month’s “Virtual Lecture,” Victor Karpyak, M.D., Ph.D., discusses the burden of alcohol use disorders (AUD) on society compared to other neuropsychiatric disorders and reviews the progress of biomarker discovery.
Ann Moyer, M.D., Ph.D., explains Mayo Clinic Labs’ new focused pharmacogenomics panel, a real-time, PCR-based testing approach that assesses 10 genes known for their drug-gene associations, to provide guidance on medication selection for patients across a variety of specialities.